Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ALXO, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Evorpacept (ALX148) | Gastric Cancer | Phase 2/3 · NCT05002127 | Completed |
| MicroRNA-10b Antagomir-Iron Oxide/Dextran-based… | HER2-positive Breast Cancer | Phase 1/2 · NCT05868226 | Recruiting |
| Eribulin | Breast Cancer, Metastatic | Phase 2 · NCT07007559 | Recruiting |
| Doxorubicin | Ovarian Cancer | Phase 2 · NCT05467670 | Active not recruiting |
| Fluorouracil | Metastatic Cancer | Phase 1 · NCT03013218 | Completed |
| Anti-EGFR/Top1i ADC ALX2004 | NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 · NCT07085091 | Recruiting |
Also used in these trials (approved or third-party drugs, not ALXO's own candidates): Trastuzumab, Ramucirumab, Paclitaxel, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Vinorelbine, Tucatinib, Pembrolizumab, Gemcitabine Hydrochloride, Cisplatin, Cetuximab, Capecitabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ALXO holds $147.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $15.4M/quarter from operations, an estimated runway of 28.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 25 · Moderate
We believe our existing cash, cash equivalents and investments will enable us to fund our operating expenses and capital expenditure requirements through the first half of 2028.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ALXO files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RA Capital Management, L.P. | Institution (13G, 5%+) | 13,117,106 | 10.15% | 2026-02-02 |
| Corey S Goodman Director, 10% owner · +40,400 options |
Insider | 12,927,442 | 10.00% | 2026-10-14 |
| venBio Partners LLC | Institution (13F) | 12,884,638 | 9.97% | 2026-09-30 |
| HBM Healthcare Investments (Cayman) Ltd. | 5%+ holder (13G) | 8,590,692 | 6.65% | 2026-03-31 |
| BlackRock, Inc. | Institution (13G, 5%+) | 7,327,850 | 5.67% | 2026-06-30 |
| Redmile Group, LLC | Institution (13F) | 7,185,263 | 5.56% | 2026-09-30 |
| Blackstone Inc | Institution (13F) | 6,775,543 | 5.24% | 2026-09-30 |
| SilverArc Capital Management, LLC | Institution (13F) | 6,565,960 | 5.08% | 2026-09-30 |
| Driehaus Capital Management, LLC | Institution (13F) | 6,025,240 | 4.66% | 2026-09-30 |
| Vanguard Capital Management LLC | Institution (13F) | 4,748,830 | 3.67% | 2026-09-30 |
| Marshall Wace LLP | Institution (13F) | 3,148,217 | 2.44% | 2026-09-30 |
| 5AM Venture Management, LLC | Institution (13F) | 3,057,325 | 2.36% | 2026-09-30 |
Share count 129,274,568 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-08-17 filed 2026-08-18 |
Lettmann Jason |
Sale (S) | 2,230 | $1.93 | 294,379 |
| 2026-08-17 filed 2026-08-18 |
Wong Shelly |
Sale (S) | 573 | $1.93 | 87,828 |
| 2026-07-01 filed 2026-07-06 |
Wong Shelly |
Sale (S) | 1,404 | $2.04 | 88,401 |
| 2026-04-16 filed 2026-04-17 |
Knight Jeff E. |
Option award (A) | 800,000 | – | – |
| 2026-04-16 filed 2026-04-17 |
Klencke Barbara |
Option award (A) | 100,000 | – | – |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ALXO and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →